Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors
2010

Mena Deficiency Delays Tumor Progression and Decreases Metastasis in Mouse Mammary Tumors

Sample size: 100 publication 10 minutes Evidence: high

Author Information

Author(s): Roussos Evanthia T, Wang Yarong, Wyckoff Jeffrey B, Sellers Rani S, Wang Weigang, Li Jiufeng, Pollard Jeffrey W, Gertler Frank B, Condeelis John S

Primary Institution: Albert Einstein College of Medicine

Hypothesis

Is Mena required for tumor progression and metastasis?

Conclusion

Mena deficiency decreases metastasis by slowing tumor progression and reducing tumor cell invasion and intravasation.

Supporting Evidence

  • Mena deficiency increased tumor latency significantly compared to Mena WT and Het mice.
  • Mena Null mice had significantly fewer tumors per animal.
  • Deficiency of Mena dampened EGF-induced in vivo invasion and motility.
  • Mena Null mice showed significantly fewer circulating tumor cells.
  • Mena Null mice had significantly fewer lung metastases compared to Mena WT and Het mice.

Takeaway

Mice without Mena take longer to develop tumors and have fewer metastases, which means they live longer.

Methodology

Mena deficient mice were intercrossed with mice expressing the polyoma middle T oncoprotein, and tumor progression was evaluated through various assays.

Limitations

The study primarily focuses on a specific mouse model, which may not fully represent human breast cancer.

Participant Demographics

Mice used in the study were genetically modified to express specific oncogenes.

Statistical Information

P-Value

<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1186/bcr2784

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication